{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:50:12Z","timestamp":1791384612682,"version":"4.3.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the clinical and angiographic responses of mycophenolate mofetil (MMF) versus methotrexate (MTX) in Takayasu arteritis (TAK).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an open-label, outcome assessor\u2013blinded trial. Adult patients with active TAK were randomized 1:1 to MMF 1\u2009g twice daily or MTX 20\u2009mg once weekly by a computer-generated program. All patients were started on 0.5\u2009mg\/kg of steroids with a predetermined tapering protocol. The primary outcome was the treatment response as defined by Indian Takayasu arteritis score at 9\u2009months. The secondary end points included the time to first failure and angiographic progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 52 patients (26 in each arm) were recruited. The rate of responders was 71.43% (15\/21) in the MMF arm and 63.64% (14\/22) in the MTX arm (P\u2009=\u2009.58). The median time to the first failure was 9\u2009months (range: 3\u20139) and 4.5\u2009months (range: 3\u20139) in the MMF and MTX arms, respectively (P\u2009=\u2009.052). In both groups, 15% of patients (n\u2009=\u20093) had a progressive disease in angiography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results showed numerically better outcomes favouring MMF, with a longer time to the first failure than MTX (9\u2009months versus 4.5\u2009months, P\u2009=\u2009.052). No significant difference was seen in the angiographic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roac157","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T16:02:11Z","timestamp":1671638531000},"page":"175-181","source":"Crossref","is-referenced-by-count":10,"title":["Clinical and angiographic outcomes of mycophenolate versus methotrexate in South Asian patients of Takayasu arteritis: Results from an open-label, outcome-assessor blinded randomized controlled trial"],"prefix":"10.1093","volume":"34","author":[{"given":"Shivraj","family":"Padiyar","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Christian Medical College , Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Danda","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Christian Medical College , Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Christian Medical College , Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Radiology, Christian Medical College , Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin M","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Christian Medical College , Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7078-9532","authenticated-orcid":false,"given":"George","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Christian Medical College , Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belavendra","family":"Antonisamy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Christian Medical College , Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"2023122314260821700_R1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/0735-1097(88)90462-7","article-title":"Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu\u2019s arteriopathy","volume":"12","author":"Ishikawa","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"2023122314260821700_R2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.injr.2015.07.009","article-title":"Takayasu\u2019s arteritis: review of epidemiology and etiopathogenesis","volume":"10","author":"Jain","year":"2015","journal-title":"Indian J Rheumatol"},{"key":"2023122314260821700_R3","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/01.CIR.90.4.1855","article-title":"Long-term outcome for 120 Japanese patients with Takayasu\u2019s disease. Clinical and statistical analyses of related prognostic factors","volume":"90","author":"Ishikawa","year":"1994","journal-title":"Circulation"},{"key":"2023122314260821700_R4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.semarthrit.2017.09.014","article-title":"Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single-center experience from a large tertiary care teaching hospital in Southern India","volume":"47","author":"Goel","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2023122314260821700_R5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0000000000000265","article-title":"Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis","volume":"28","author":"Koster","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2023122314260821700_R6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.1780370420","article-title":"Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate","volume":"37","author":"Hoffman","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2023122314260821700_R7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10067-009-1333-6","article-title":"Mycophenolate mofetil in Takayasu\u2019s arteritis","volume":"29","author":"Goel","year":"2010","journal-title":"Clin Rheumatol"},{"key":"2023122314260821700_R8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s10067-007-0596-z","article-title":"Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis","volume":"26","author":"Shinjo","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2023122314260821700_R9","first-page":"1793","article-title":"Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu\u2019s arteritis","volume":"30","author":"Valsakumar","year":"2003","journal-title":"J Rheumatol"},{"key":"2023122314260821700_R10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","article-title":"The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2023122314260821700_R11","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0167-5273(96)88783-3","article-title":"Diagnostic criteria for Takayasu arteritis","volume":"54","author":"Sharma","year":"1996","journal-title":"Int J Cardiol"},{"key":"2023122314260821700_R12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2215\/CJN.02820707","article-title":"Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients","volume":"2","author":"Cattaneo","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023122314260821700_R13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","article-title":"Takayasu arteritis","volume":"120","author":"Kerr","year":"1994","journal-title":"Ann Intern Med"},{"key":"2023122314260821700_R14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023122314260821700_R15","doi-asserted-by":"crossref","DOI":"10.1186\/s42358-019-0087-3","article-title":"Translation and validation of the Indian Takayasu clinical activity score (ITAS2010) for the Brazilian Portuguese language","volume":"59","author":"Fritsch","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2023122314260821700_R16","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/ket128","article-title":"Indian Rheumatology Vasculitis (IRAVAS) group. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010)","volume":"52","author":"Misra","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2023122314260821700_R17","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0167-5273(96)88780-8","article-title":"Current status of Takayasu arteritis in India","volume":"54","author":"Jain","year":"1996","journal-title":"Int J Cardiol"},{"key":"2023122314260821700_R18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/acr.24632","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023122314260821700_R19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023122314260821700_R20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023122314260821700_R21","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320975233","article-title":"Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis","volume":"11","author":"Wu","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"2023122314260821700_R22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0961203321995238","article-title":"Cotrimoxazole prophylaxis prevents major infective episodes in patients with systemic lupus erythematosus on immunosuppressants: a non-concurrent cohort study","volume":"30","author":"Ganu","year":"2021","journal-title":"Lupus"},{"key":"2023122314260821700_R23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7326\/0003-4819-130-5-199903020-00013","article-title":"Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases","volume":"130","author":"Daina","year":"1999","journal-title":"Ann Intern Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac157\/48486721\/roac157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/175\/54800050\/roac157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/175\/54800050\/roac157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T09:26:24Z","timestamp":1703323584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/1\/175\/6953327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2023,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac157","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2022,12,21]]}}}